Adherence to disease modifying therapies in patients with multiple sclerosis
Introduction. Multiple sclerosis is an inflammatory demyelinating disease of the central nervous system. Disease modifying treatment tends to reduce the risk for relapses rate and disease progression, therefore adherence to treatment is essential for outcome. Aim of the study. To examine adherence...
Saved in:
Main Authors: | D. Pileckė, N. Giedraitienė |
---|---|
Format: | Article |
Language: | English |
Published: |
Vilnius University Press
2019-06-01
|
Series: | Neurologijos seminarai |
Subjects: | |
Online Access: | https://www.journals.vu.lt/neurologijos_seminarai/article/view/27791 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Recommendations for the treatment of multiple sclerosis with disease-modifying drugs during the COVID-19 pandemic
by: R. Kizlaitienė, et al.
Published: (2020-06-01) -
Administration and Monitoring Burden of High-Efficacy Disease-Modifying Therapies for Multiple Sclerosis: A Delphi Consensus of Clinical Experts from Saudi Arabia
by: Seraj Makkawi, et al.
Published: (2025-01-01) -
From pathogenesis to new developments in treatment of primary progressive multiple sclerosis. Literature review
by: A. Juknelytė, et al.
Published: (2020-03-01) -
Long-Term Safety and Effectiveness of Dimethyl Fumarate in Patients with Multiple Sclerosis Treated in Routine Medical Practice: Final Analysis of the ESTEEM Study
by: Krupa Shah Pandey, et al.
Published: (2024-12-01) -
Role of microglia in the pathogenesis of multiple sclerosis and links to immunomodulatory therapy
by: P. Valiukevičius, et al.
Published: (2023-10-01)